Lisa N. Henning, Sarah Carpenter, Gregory V. Stark, Natalya V. Serbina
Antimicrobial Agents and Chemotherapy Jan 2018, 62 (2) e01590-17; DOI: 10.1128/AAC.01590-17
Nagy, C., Mondick, J., Serbina, N., Casey, L., Carpenter, S., French, J. and Guttendorf, R.
Clinical And Translational Science. Volume 10, Issue 1, January 2017, Pages 12–19. doi:10.1111/cts.12433
Brent J. Yamamoto, Annette M. Shadiack, Sarah Carpenter, Daniel Sanford, Lisa N. Henning, Edward O’Connor, Nestor Gonzales, John Mondick, Jonathan French, Gregory V. Stark, Alan C. Fisher, Leslie S. Casey and Natalya V. Serbina
Antimicrob. Agents Chemother. October 2016 vol. 60 no. 10 5787-5795
Brent J. Yamamoto, Annette M. Shadiack, Sarah Carpenter, Daniel Sanford, Lisa N. Henning, Nestor Gonzales, Edward O’Connor, Leslie S. Casey and Natalya V. Serbina
Antimicrob. Agents Chemother. October 2016 vol. 60 no. 10 5796-5805
Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies
Christa F. Nagy, PhD, Timothy S. Leach, MD, MPH, Joseph H. Hoffman, MD, Arthur Czech, BS, Sarah E. Carpenter, PhD, Robert Guttendorf, RPh, PhD
Clinical Therapeutics/September 2016 Volume 38, Issue 9, Pages 2083-2097
Posters, 2016 ASM Biodefense and Emerging Diseases Research Meeting Presentations, February 8-10, 2016
Animal to Human Dose Translation under the Animal Rule – Obiltoxaximab (ETI-204) Case Study
C. Nagy1, J. Mondick2, N. Serbina1, L. Casey1and R. Guttendorf3
1Elusys Therapeutics Inc., Pine Brook, NJ; 2Metrum Research Group LLC, Tariffville, CT; 3Aclairo Pharmaceutical Development Group Inc., Vienna, VA
Safety, Pharmacokinetics and Immunogenicity of Intramuscular (IM) Administration of Obiltoxaximab (ETI-204) to Healthy Humans
A.Czech1, J. Mondick2, R. Guttendorf3, A. King4 and C. Nagy1
1Elusys Therapeutics Inc., Pine Brook, NJ; 2Metrum Research Group LLC, Tariffville, CT; 3Aclairo Pharmaceutical Development Group Inc., Vienna, VA; 4Covance Clinical Research Unit, Inc., Dallas, TX
The use of meta-analysis approach to demonstrate added benefit of Obiltoxaximab (ETI-204) in treatment of inhalational anthrax
N. Serbina1, G. Stark2, A. Fisher3, L. Casey1, R. Slay4, and R. Conrad1
1Elusys Therapeutics, Inc., Pine Brook NJ, 2Battelle BioMed. Res. Ctr., Columbus, OH, 3BDM Consulting, Inc., 4NIAID/NIH
Presented at 2015 ASM Biodefense and Emerging Diseases Research Meeting, Washington, DC, February 9-11, 2015
Obiltoxaximab (ETI-204) Efficacy across a Spectrum of Disease Severity in a Trigger-to-Treat Cynomolgus Monkey Inhalational Aerosol Challenge Model of Anthrax
B. Yamamoto1, N. Serbina1, S. Carpenter1, D. Sanford2, G. Stark2, A. Shadiack1,3, and L. Casey1
1Elusys Therapeutics, Inc., Pine Brook NJ, 2Battelle, Columbus OH, 3Currently at Therapeutics MD, Inc
You are now leaving www.Elusys.com, a site provided by Elusys Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Elusys Therapeutics, Inc. does not endorse and/or influence the content found on websites not owned/operated by Elusys Therapeutics, Inc.
You are now leaving www.Elusys.com, a site provided by Elusys Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Elusys Therapeutics, Inc. does not endorse and/or influence the content found on websites not owned/operated by Elusys Therapeutics, Inc.
You are now leaving www.Elusys.com, a site provided by Elusys Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Elusys Therapeutics, Inc. does not endorse and/or influence the content found on websites not owned/operated by Elusys Therapeutics, Inc.
You are now leaving www.Elusys.com, a site provided by Elusys Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Elusys Therapeutics, Inc. does not endorse and/or influence the content found on websites not owned/operated by Elusys Therapeutics, Inc.
You are now leaving www.Elusys.com, a site provided by Elusys Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Elusys Therapeutics, Inc. does not endorse and/or influence the content found on websites not owned/operated by Elusys Therapeutics, Inc.
You are now leaving www.Elusys.com, a site provided by Elusys Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Elusys Therapeutics, Inc. does not endorse and/or influence the content found on websites not owned/operated by Elusys Therapeutics, Inc.
You are now leaving www.Elusys.com, a site provided by Elusys Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Elusys Therapeutics, Inc. does not endorse and/or influence the content found on websites not owned/operated by Elusys Therapeutics, Inc.
You are now leaving www.Elusys.com, a site provided by Elusys Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Elusys Therapeutics, Inc. does not endorse and/or influence the content found on websites not owned/operated by Elusys Therapeutics, Inc.